Who We Are
At Limitless Ventures, we are independent impact investors focused on solving deeply entrenched societal challenges—particularly Mental Health and Substance Use Disorder. These issues persist not due to a lack of solutions, but because the system is fundamentally misaligned. We believe that true progress requires aligning all stakeholders—patients, providers, and payers—while generating sustainable financial returns.
To achieve this, we take a lifecycle approach and have built a uniquely structured investment platform. We partner with top-tier teams across Venture Capital, Private Equity, and Real Estate while integrating an in-house medical team to bridge the gap between financial incentives and patient outcomes. Every investment we make is structured as a Special Purpose Vehicle (SPV), ensuring flexibility, focus, and accountability.
Our Impact & Vision
Since 2017, we have invested $30M+ across 27 transactions, generating $16M in Distributions to Paid-In Capital (DPI/O’d) while positively impacting 120,000+ lives. Our mission is ambitious but clear:
Improve 500,000 lives in the U.S. by 2030
Impact 1% of the mental health population (~4 million people) by 2040
We achieve this through investments across three interconnected asset classes:
Venture Capital – Backing early-stage innovation
Buyout (Private Equity) – Scaling proven models
Real Estate – Creating infrastructure for long-term change
Why Mental Health & Addiction Persist
Mental health is both deeply personal and highly systemic—which is why one-size-fits-all solutions fail. Some of the biggest barriers to change include:
1) The Snowflake Problem
Every person struggling with mental health or addiction is unique—like a snowflake. But at scale, they are all snowflakes—part of a massive and fragmented market:
Total Addressable Market (TAM): 60M+ people
Serviceable Addressable Market (SAM): 20M+ people
Serviceable Obtainable Market (SOM): 2M+ people
The challenge is creating systems that can scale without losing personalization.
2) Stakeholder Misalignment
Patients need care. Providers want to help. Payers manage risk. But their incentives rarely align.
Patients want access to treatment.
Providers need financial sustainability.
Payers (insurers) profit by minimizing payouts.
This misalignment leads to gaps in care, inadequate treatment, and financial inefficiencies.
3) Uninvestable Complexity
Mental health is not just a healthcare issue—it spans biotech, real estate, workforce development, public markets, and social services. The Center for Disease Control (CDC) calls these indirect healthcare issues, the Social Determinants of Health (SDoH). Investing in solutions requires expertise across multiple disciplines and industries, which few investors possess. Fortunately, we have deep domain expertise in each of this verticals, built very slowly over decades by individual family business. (Maybe, there was a high consciousness at work, architecting the whole thing, and we didn’t even know it).
4) The Long Tail of Solutions
History shows that solving major public health crises takes generations, not years.
Alcohol is essentially in our blood:
Alcoholism began over 2,000 years ago when alcohol was the safest liquid to drink.
September 14, 1787, three days before signing, the U.S. Constitution, George Washington and other delegates celebrated the completed draft at City Tavern in Philadelphia, running up a massive tab for over 100 gallons of alcohol. The 55 attendees consumed 54 bottles of Madeira, 60 bottles of claret, 8 bottles of whiskey, 22 bottles of porter, 8 bottles of cider, 12 bottles of beer, and 7 large bowls of alcoholic punch.
Waterborne diseases (cholera, typhoid, dysentery) plagued societies until 1899, when Kohler Water Works introduced the bubbler, making clean water widely available.
Essentially, alcoholism and the variety of Mental health issue that spawn before, during and after, have devloped over a long time. As such, the solutions must have similar long time horizons (20+ years), which don't fit neatly into traditional investment mandates. Therefore, our LP base is primarily Single Famliy Offices with a long (30yr+) view.
5) Incumbent Resistance: The Alcohol & Tobacco Playbook
Many industries don’t just resist disruption—they actively perpetuate the problem.
Alcohol has grown at a 10% CAGR from $300M in 1933 to $1.7T in 2023.
Tobacco has sustained a 3.28% CAGR from $5B in 1933 to $75B in 2023.
These industries don’t disappear—they evolve (e.g., vaping, cannabis, "healthier" alcohol alternatives). Meanwhile, mental health solutions struggle for funding, even as the market grows.
Our Lifecycle Approach: Investing Across the Continuum
To break these cycles, we invest across the full continuum of problems and solutions, aligning value-based outcomes with financial returns. Our framework is inspired by the Determinants of Health (DoH) model defined by the CDC, broken into three major investment categories:
Innovation: typically [Seed ($250K)/Series A ($500K)] VC Preferred Equity:
Life Sciences (i.e: biotech and medical devices for poly-substance abuse)
Technology (i.e: Software/AI making at-home-healthcare better)
Internet of Things (i.e: Smart watch which provides behavioral data)
Distribution: typically Private Equity (70% Pref. Equity) on $1-4M EBITDA.
Treatment (i.e: Detox, PHP, IoP, OP)
Professional Development (i.e: Skill upleveling, Re-entry placement)
Longevity: typically Real Estate Ground-Up Projects (200k to 500k Sq.Ft.)
Wellness housing (i.e.: Mixed-Use multi-family in Urban enviornments)
Food as Medicine (i.e: Organic Food at In-Organic prices)
By timing investments correctly and integrating expertise across disciplines, we create sustainable change while generating uncorrelated, high-alpha returns
History
Generally, but not explicitly, we focus our time energy and effort on deals within the fields of we have domain expertise. Some indications of deals we have funded in the past include the following areas:
Healthcare:
Depression
Suicidal Ideation
Bi-Polar
Substance Use Disorder (Alcohol, Opioids, Cocaine & Nicotine)
Process Addictions (Obesity, Gambling, Gaming)
Covid-19
Parkinsons
Kidney Disease
Investment Criteria: What We Look For
We back mission-driven companies that meet these key criteria:
Market: Large, growing, and unmet need
Solution: Unique, defensible, and scalable
Economics: Strong unit economics and financial sustainability
Team: Led by repeat entrepreneurs with successful exits
Resources: Backed by institutional capital with domain expertise
As active partners, we go beyond capital—taking board seats, advisory roles, and operational positions to drive execution and impact.
As a team who is seeking people with a partner mindset, we are relentlessly focused on mutual success. Therefore, we often role up our sleeves, take board seats, advisory positions or CxO roles while leveraging our network to drive unparalleled access, insights and operational execution.
Performance & Track Record
Median time to capital return: 2.25 years
Investor DPI: Up to 2.4x within this timeframe
TVPI/O: $18M/$16.75M
Transactions/Unqiue Deals: 34/20
Timeline: 12–16 weeks
Governance: Approval by Medical Team → Investment Committee → LPAC
Historical structure: 1/3 lead, 1/3 co-lead, 1/3 follow-on from institutional investors
Values
We believe in "radical responsibility" with our capital, time, and expertise. Our values prioritize:
De-risking in the short-run (use Non-Dilutive capital, Diversification through Ef
Maximize the Effiency Frontier over the long-run (identify positions to supersize through major co-investing)
Positive Externalities—creating win-win solutions for stakeholders and shareholders/investors.
Final Thought
We’re not just investing in companies. We’re investing in change.
We welcome conversations with mission-aligned partners who share our vision. If you believe in doing good by doing well, let’s talk.
Sincerely,
Limitless Ventures Management Team
Mantra: Healthy People, Healthy Planet
Email: info@limitlessventures.us